IMRN - Immuron inks SARS-CoV-2 research agreement with Monash University shares +12%

Immuron (IMRN) rises 12% premarket after providing an update on progress of the anti-viral activity of IMM-124E. A new research services agreement has been executed with Monash University to advance the SARS-CoV-2 findings and to further research and identify the inhibitory substance/s in IMM-124E. The research team will utilize two new recombinant reagents, obtained from Melbourne’s Peter Doherty Institute for Infection and Immunity to initiate the research work and to develop a suitable assay for evaluating the inhibitory efficacy of IMM-124E.

For further details see:

Immuron inks SARS-CoV-2 research agreement with Monash University, shares +12%